Skip to main content
US EQUITIES OPEN CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
BN

BNTXStockBioNTech SE

Nasdaq Global Select Market · Healthcare · DE

$84.08 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment BNTX's does — no target price to set, unlike a price alert.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 91.3% aligned
VWAPPrice below VWAP ($85.32)
VolumeRelative volume 4.2× the 20-day average
Momentum10-day rate of change -7.3%
Market & analysts

Still fetching analyst coverage — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

Momentum (10d)
-7.3%
rate of change
SMC grade
C · 50
91.3% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
C · 50
SMC grade — 91.3% timeframe alignment
-7.3%
Rate of change (10d)

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for BNTX — this runs off the critical path so the page paints first. It will appear here on its own.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Tracked investors holding BNTX
InvestorFirmPositionWeightAs of
Dodge & Cox Dodge & Cox $363M 0.2% 2026-09-30
Ken Griffin Citadel Advisors $129M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $96M 0.0% 2026-09-30
Israel Englander Millennium Management $65M 0.0% 2026-09-30
Steven Cohen Point72 Asset Management $41M 0.0% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $1M 0.0% 2026-09-30
Jefferies Jefferies Financial Group $1M 0.0% 2026-09-30
Baillie Gifford Baillie Gifford & Co $1M 0.0% 2026-09-30
Ron Baron Baron Capital (BAMCO) $0M 0.0% 2026-09-30
Cathie Wood ARK Investment Management $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

119.34110.47101.6192.7483.882025-11-182026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
83.07
S2
83.69
S1
84.28
PIVOT
84.90
R1
85.49
R2
86.11
R3
86.70

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
90.18 – 106.96
±8.51% from 98.57, made 2026-09-29 · resolves 2026-10-06
BUY
from 19 indicators
77.1% of our last 20463 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.1% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)36.80NEUTRAL
Stochastic %K (14)1.24BUY
CCI (20)-164.49BUY
Williams %R (14)-98.76BUY
MACD (12,26,9)-0.03SELL
ROC (10)-7.53SELL
Momentum (10)-6.82SELL
EMA (10)85.91SELL
SMA (10)86.04SELL
EMA (20)87.38SELL
SMA (20)87.13SELL
EMA (30)88.79SELL
SMA (30)88.49SELL
EMA (50)90.83SELL
SMA (50)92.15SELL
EMA (100)93.15SELL
SMA (100)94.44SELL
EMA (200)95.24SELL
SMA (200)95.35SELL

About BioNTech SE

Healthcare · Biotechnology

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

biontech.de ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 43
⏰ 4H BEARISH 43
🕐 1H BEARISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-7.3%
Rate of change (10d)
4.2×
Volume vs its 20-day average
-2.35
MACD (no fresh cross)
$84.05
Volume POC (today)
$83.82 – $84.74
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Still fetching insider filings — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.